Inventor · disambiguated record
Lili Feng
Also filed as: FENG LILI
15 granted patents·14 pending applications·134 citations·filing 1995–2025
92Inventor score
Files withNOVARTIS AG7FENG LILI6BEBERNITZ GREGORY RAYMOND5NOVARTIS PHARMACEUTICALS CORP5JUNLEBAO DAIRY GROUP CO LTD2
Top patents by PatentIndex Score
29 records- 0196US8877938B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2006·Granted Nov 4, 2014·44 cites·14 claims
- 0291US2025339395A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2024·Application pending·0 cites
- 0390US8163704B2Glycoside derivatives and uses thereofBEBERNITZ GREGORY RAYMOND·Filed 2010·Granted Apr 24, 2012·15 cites·72 claims
- 0486US9388134B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2014·Granted Jul 12, 2016·5 cites·15 claims
- 0585US8828951B2Glycoside derivatives and uses thereofBEBERNITZ GREGORY RAYMOND·Filed 2012·Granted Sep 9, 2014·7 cites·22 claims
- 0684US11642329B2Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Granted May 9, 2023·0 cites·2 claims
- 0784US8466114B2Glycoside derivatives and uses thereofBEBERNITZ GREGORY RAYMOND·Filed 2012·Granted Jun 18, 2013·6 cites·22 claims
- 0883US2022257551A1Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Application pending·0 cites
- 0981US11096918B2Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Granted Aug 24, 2021·0 cites·2 claims
- 1079US2021361610A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 1177US9309229B2Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamineFENG LILI·Filed 2011·Granted Apr 12, 2016·3 cites·26 claims
- 1273US5731343AMethod of use of radicicol for treatment of immunopathological disordersSCRIPPS RESEARCH INST·Filed 1995·Granted Mar 24, 1998·48 cites·8 claims
- 1372US2019374498A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1472US2019374497A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1570USRE49080EGlycoside derivatives and uses thereofNOVARTIS AG·Filed 2020·Granted May 24, 2022·0 cites·35 claims
- 1669US2018344679A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1762US2016324821A1Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2016·Application pending·0 cites
- 1862US2014274921A1Glycoside derivatives and uses thereofBEBERNITZ GREGORY RAYMOND·Filed 2014·Application pending·0 cites
- 1961US9895389B2Glycoside derivatives and uses thereofNOVARTIS AG·Filed 2016·Granted Feb 20, 2018·0 cites·4 claims
- 2059US10093665B2Solid oral formulations and crystalline forms of an inhibitor of apoptosis proteinNOVARTIS AG·Filed 2016·Granted Oct 9, 2018·0 cites·27 claims
- 2159US9540363B2Solid oral formulations and crystalline forms of an inhibitor of apoptosis proteinYANG DONG·Filed 2013·Granted Jan 10, 2017·0 cites·22 claims
- 2259US2025161379A1Bifidobacterium animalis subsp. lactis i797, method for separation and purification thereof, and use thereofJUNLEBAO DAIRY GROUP CO LTD·Filed 2025·Application pending·0 cites
- 2357US2018370960A1Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis ProteinNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2454US2015141354A1Glycoside derivatives and uses thereofBEBERNITZ GREGORY RAYMOND·Filed 2015·Application pending·0 cites
- 2554US2023034193A1Bifidobacterium animalis subsp. lactis i797, method for separation and purification thereof, and use thereofJUNLEBAO DAIRY GROUP CO LTD·Filed 2020·Application pending·0 cites
- 2649US8623385B2Solid oral formulations and crystalline forms of an inhibitor of apoptosis proteinTHAKUR JEEWAN·Filed 2010·Granted Jan 7, 2014·0 cites·5 claims
- 2745US2009131528A1SaltFENG LILI·Filed 2007·Application pending·0 cites
- 2844US7067472B1Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodiesSCRIPPS RESEARCH INST·Filed 1997·Granted Jun 27, 2006·6 cites·5 claims
- 2943US2016175305A1Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamineFENG LILI·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lili Feng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →